- Home
- RPRX vs SNN Comparison
RPRX vs SNN Comparison
Compare RPRX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- SNN
- Stock Information
- Founded
- RPRX 1996
- SNN 1856
- Country
- RPRX United States
- SNN United Kingdom
- Employees
- RPRX N/A
- SNN N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- RPRX Health Care
- SNN Health Care
- Exchange
- RPRX Nasdaq
- SNN Nasdaq
- Market Cap
- RPRX 16.2B
- SNN 15.2B
- IPO Year
- RPRX 2020
- SNN 1999
- Fundamental
- Price
- RPRX $40.42
- SNN $36.76
- Analyst Decision
- RPRX Strong Buy
- SNN Hold
- Analyst Count
- RPRX 3
- SNN 4
- Target Price
- RPRX $46.00
- SNN $33.50
- AVG Volume (30 Days)
- RPRX 2.8M
- SNN 631.7K
- Earning Date
- RPRX 11-05-2025
- SNN 10-30-2025
- Dividend Yield
- RPRX 2.18%
- SNN 1.99%
- EPS Growth
- RPRX N/A
- SNN 59.91
- EPS
- RPRX 1.77
- SNN 0.56
- Revenue
- RPRX $2,349,553,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- RPRX $36.16
- SNN $7.85
- Revenue Next Year
- RPRX $2.04
- SNN $5.43
- P/E Ratio
- RPRX $22.85
- SNN $65.86
- Revenue Growth
- RPRX 3.69
- SNN 5.35
- 52 Week Low
- RPRX $24.05
- SNN $23.69
- 52 Week High
- RPRX $41.00
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- RPRX 74.39
- SNN 54.85
- Support Level
- RPRX $35.92
- SNN $35.74
- Resistance Level
- RPRX $37.40
- SNN $37.06
- Average True Range (ATR)
- RPRX 1.09
- SNN 0.47
- MACD
- RPRX 0.26
- SNN 0.08
- Stochastic Oscillator
- RPRX 91.94
- SNN 57.75
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.